4-(2-氯苯基)-吡咯烷-2-酮 | 28311-22-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 4-(2-氯苯基)-吡咯烷-2-酮
• 中文别名: 4-(2-氯苯基)吡咯烷-2-酮
• 英文名称: 4-(2-chlorophenyl)pyrrolidin-2-one
• 英文别名: 4-(2-Chlorphenyl)-pyrrolidin-2-on
• CAS: 28311-22-0
• 化学式: C₁₀H₁₀ClNO
• 分子量: 195.648
• InChiKey: BVCDQJGBLFWXEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933790090

反应信息

• 作为反应物：
  描述：

  7-溴-2,3,4,5-四氢-1H-苯并[d]氮杂卓 、 4-(2-氯苯基)-吡咯烷-2-酮 在 potassium phosphate 、 copper(l) iodide 、 trans-N,N-dimethyl-cyclohexane-1,2-diamine 、 potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 生成 4-(2-chlorophenyl)-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)pyrrolidin-2-one
  参考文献：
  名称：

  Lactam and oxazolidinone derived potent 5-hydroxytryptamine 6 receptor antagonists

  摘要：

  Lactam and oxazolidinone derived potent 5-hydroxytryptamine 6 (5-HT6) receptor antagonists have been disclosed. One potent member from the lactam series, racemic compound 14 (K-i of 2.6 nM in binding assay, IC50 of 15 nM in functional cAMP antagonism assay) was separated into corresponding enantiomers that displayed the effect of chirality on binding potency (K-i of 1.6 nM and 3000 nM, respectively). The potent enantiomer displayed an IC50 of 8 nM in cAMP antagonism assay, selectivity against a number of family members as well as brain permeability in rats after 6 h post oral administration. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.049
• 作为产物：
  描述：

  2-(1-(2-氯苯基)-2-硝基乙基)丙二酸二乙酯 在 氢气 、 sodium hydroxide 作用下， 以 甲醇 、 乙醇 、 甲苯 为溶剂， 20.0 ℃ 、413.7 kPa 条件下， 反应 55.5h， 生成 4-(2-氯苯基)-吡咯烷-2-酮
  参考文献：
  名称：

  β-芳基-γ-内酰胺的有效合成及其与（S）-萘普生的拆分：（R）-和（S）-巴氯芬的制备

  摘要：

  描述了对映异构纯 β-芳基-γ-内酰胺的有效合成。这种合成的主要特征是 β-芳基-γ-内酰胺与 (S)-萘普生的实际拆分。该程序基于硝基甲烷与亚苄基丙二酸酯的迈克尔加成，这很容易获得，然后在雷尼镍的存在下还原 γ-硝基酯，然后进行皂化/脱羧反应。该方法的实用性通过制备对映异构纯的 (R) - 和 (S) - 巴氯芬盐酸盐而得到强调。

  DOI：

  10.3390/molecules201219830

文献信息

• Catalytic, asymmetric azidations at carbonyls: achiral and <i>meso</i>-anhydride desymmetrisation affords enantioenriched γ-lactams
  作者：Simon N. Smith、Cristina Trujillo、Stephen J. Connon

  DOI：10.1039/d2ob01040b

  日期：——

  of azide to meso-anhydrides has been developed, promoted by novel sulfamide-substituted Cinchona alkaloid-based catalysts. Readily available glutaric anhydrides can be smoothly converted to enantioenriched hemi-acyl azides and from there to either γ-amino acids or γ-lactams.

  已经开发了一种前所未有的有机催化工艺，该工艺涉及将叠氮化物不对称加成到内消旋酸酐中，并由新型磺酰胺取代的金鸡纳生物碱基催化剂促进。容易获得的戊二酸酐可以顺利转化为富含对映体的半酰基叠氮化物，然后再转化为 γ-氨基酸或 γ-内酰胺。
• Potent and selective α1A adrenoceptor partial agonists—Novel imidazole frameworks
  作者：Gavin A. Whitlock、Paul E. Brennan、Lee R. Roberts、Alan Stobie

  DOI：10.1016/j.bmcl.2009.03.162

  日期：2009.6

  Novel imidazole frameworks have been identified as potent partial agonists of the alpha(1A) adrenergic receptor, with good selectivity over the alpha(1B), alpha(1D) and alpha(2A) receptor sub-types. Nitrile 28 possessed attractive CNS drug-like properties with good membrane permeability and no P-pg mediated efflux. 28 also possessed excellent solubility, metabolic stability and wide ligand selectivity. (C) 2009 Elsevier Ltd. All rights reserved.
• US4556674A
  申请人：——

  公开号：US4556674A

  公开（公告）日：1985-12-03
• US4699918A
  申请人：——

  公开号：US4699918A

  公开（公告）日：1987-10-13
• Lactam and oxazolidinone derived potent 5-hydroxytryptamine 6 receptor antagonists
  作者：Greg Hostetler、Derek Dunn、Beth Ann McKenna、Karla Kopec、Sankar Chatterjee

  DOI：10.1016/j.bmcl.2014.03.049

  日期：2014.5

  Lactam and oxazolidinone derived potent 5-hydroxytryptamine 6 (5-HT6) receptor antagonists have been disclosed. One potent member from the lactam series, racemic compound 14 (K-i of 2.6 nM in binding assay, IC50 of 15 nM in functional cAMP antagonism assay) was separated into corresponding enantiomers that displayed the effect of chirality on binding potency (K-i of 1.6 nM and 3000 nM, respectively). The potent enantiomer displayed an IC50 of 8 nM in cAMP antagonism assay, selectivity against a number of family members as well as brain permeability in rats after 6 h post oral administration. (C) 2014 Elsevier Ltd. All rights reserved.